80岁以上非小细胞肺癌患者的真实世界管理与结局:十年演变
基于法国KBP-2010和KBP-2020两个前瞻性全国队列,比较2010年与2020年≥80岁NSCLC患者的临床特征、治疗和生存变化。2020年队列中≥80岁患者占13.0%,十年间局限期手术比例从26.0%升至46.4%,局部晚期放化疗从10.6%升至19.1%,转移期全身治疗从52.1%升至55.9%且靶向治疗比例增加,4年总生存率从6.3%提高至13.1%(p<0.0001)。
要点
- ≥80岁NSCLC患者中转移性疾病占62.3%,ECOG≥2占40.4%。
- 十年间局限期手术和局部晚期放化疗比例显著增加。
- 转移期靶向治疗比例上升而化疗比例下降,4年OS从6.3%升至13.1%。
核心结论
- 2010至2020年间≥80岁NSCLC患者治疗可及性改善,生存结局显著提高。
研究设计与样本
- 基于法国KBP-2010和KBP-2020前瞻性全国队列,比较2010年与2020年确诊的≥80岁NSCLC患者。
- KBP-2020队列共8941例患者,其中NSCLC 7797例,≥80岁者1017例(13.0%)。
主要发现
- ≥80岁患者中女性占33.7%,ECOG体能状态≥2占40.4%,从不吸烟者占32.4%。
- 疾病分期为局限期18.9%、局部晚期18.8%、转移性62.3%。
- 分子检测人群中激活EGFR突变最常见,占25.8%。
- 局限期手术比例从26.0%升至46.4%,局部晚期放化疗从10.6%升至19.1%。
- 转移期全身治疗从52.1%升至55.9%,靶向治疗从14.9%升至19.5%,化疗从51.2%降至24.6%。
临床怎么用
- ≥80岁NSCLC患者应积极评估分子分型以指导靶向治疗。
- 对局限期和局部晚期患者可考虑手术或放化疗等积极局部治疗。
- 转移期治疗模式向靶向治疗倾斜,化疗使用减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The proportion of patients aged ≥ 80 years with non-small-cell lung cancer (NSCLC) is rising, yet data on their management remain scarce. This study analysed changes in treatment and survival in this population over a decade. METHODS: The KBP-2010 and KBP-2020 cohorts are prospective, nationwide cohorts including patients diagnosed with primary lung cancer in France in 2010 and 2020, respectively. We compared the clinical characteristics, treatments and outcomes of KBP patients aged ≥ 80 years with NSCLC between 2010 and 2020. RESULTS: Among 8941 patients in KBP-2020, 7797 presented NSCLC and 1017 (13.0%) were ≥ 80 years, of whom 33.7% were women, 40.4% had ECOG performance status ≥ 2 and 32.4% were never-smokers. Most patients had metastatic disease (localized 18.9%, locally advanced 18.8%, metastatic 62.3%). Among patients who underwent molecular screening, the most frequent alterations were activating EGFR mutations (25.8%). Between 2010 and 2020, significant increases were seen in the numbers of patients undergoing surgery for localized disease (26.0% vs 46.4%) and chemoradiotherapy for locally advanced disease (10.6% vs 19.1%). In metastatic disease, the use of systemic therapy increased from 52.1% of patients in 2010-55.9% in 2020, with a shift towards targeted therapies (from 14.9% to 19.5%), while the use of chemotherapy decreased (from 51.2% to 24.6%). Four-year overall survival rate improved from 6.3% in 2010-13.1% in 2020 (p < 0.0001). CONCLUSION: Patients ≥ 80 years with NSCLC exhibit specific clinical and molecular profiles. Access to therapies improved over the decade 2010-2020, leading to significantly better survival outcomes.
引用
- Corre R, Monnet I, Moreau L, et al. Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution. Eur J Cancer. 2026. PMID: 42235466. doi:10.1016/j.ejca.2026.116845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。